Next |
home / stock / fate / fate message board
Subject | By | Source | When |
---|---|---|---|
AFM28 - ADCP. | NY1972 | investorshub | 04/27/2023 4:11:19 PM |
Some CEOs won't even PR. $AFMD was a | NY1972 | investorshub | 04/27/2023 1:29:34 AM |
A letter (dated April 4th) was received saying | jondoeuk | investorshub | 04/26/2023 3:50:11 AM |
It has advantages as multiple edits can result | jondoeuk | investorshub | 04/26/2023 3:10:01 AM |
whytestocks: $FATE News Article - Fate Therapeutics to Webcast Conference Call Reporting First Quart | whytestocks | investorshangout | 04/24/2023 6:20:48 PM |
If you listen to $DTIL CSO who just | NY1972 | investorshub | 04/22/2023 7:21:10 PM |
TME is poorly understood. Mgt. is crossing a | NY1972 | investorshub | 04/22/2023 7:17:39 PM |
Clearly active (I wonder if they plan to | jondoeuk | investorshub | 04/22/2023 1:13:11 AM |
An IIT (in China) testing this (using the | jondoeuk | investorshub | 04/22/2023 1:06:17 AM |
Depends on the edits. The authors go on | jondoeuk | investorshub | 04/22/2023 1:01:26 AM |
Endless edits still doesn't address the infection that | NY1972 | investorshub | 04/20/2023 5:49:22 PM |
What is the impact of multiple edits on | NY1972 | investorshub | 04/20/2023 12:33:42 AM |
Some more info on CLASH https://www.liebertpub.com/doi/10.1089/crispr.2023.0003 | jondoeuk | investorshub | 04/19/2023 11:13:06 PM |
The poster | jondoeuk | investorshub | 04/19/2023 7:34:24 PM |
I was hoping they would have focused on | jondoeuk | investorshub | 04/19/2023 7:30:11 PM |
Out 6.60-6.65, $$$$$ | harry crumb | investorshub | 04/18/2023 7:08:51 PM |
ICE that does ADCP has value. AFM 13 | NY1972 | investorshub | 04/17/2023 12:10:38 AM |
CAR NK looks like CART. What is the | NY1972 | investorshub | 04/13/2023 2:04:51 PM |
I can see why they chose the targets | jondoeuk | investorshub | 04/11/2023 8:07:44 PM |
In this, the authors show that iPSC-derived NKs | jondoeuk | investorshub | 04/05/2023 9:59:32 PM |
News, Short Squeeze, Breakout and More Instantly...
Fate Therapeutics Inc. Company Name:
FATE Stock Symbol:
NASDAQ Market:
Fate Therapeutics Inc. Website:
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
First Lupus Patient Treated with FT819 CAR T-cell Product Candidate in Phase 1 Autoimmunity Study; Future Clinical Development of FT819 to Focus Exclusively on Autoimmune Disease Enrollment Initiated with FT522 CAR NK Cell Product Candidate in Conditioning-free Treatment Arm of Phase 1 ...
Pre-treatment Sample of Patient’s Blood Showed Rapid and Potent Depletion of CD19+ B Cells in Ex Vivo Cytotoxicity Assay with FT819 Translational Data from FT819 Phase 1 B Cell Malignancies Study Support Key Therapeutic Mechanisms of Activity for B Cell-mediated Autoimmune Diseas...